A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant

Korábbi kezelés

• Patients who have undergone previous allo-HCT.

Más betegség

• Patients with active extramedullary disease.
• Patients with active central nervous system malignancy.
• Uncontrolled infection at the time of allo-HCT.
• Patient seropositivity for HIV I/II and/or HTLV I/II.

Egyéb

• Females who are pregnant or breastfeeding.
• Patients unwilling to use contraception during the study period.
• Patient or parent or guardian unable to give informed consent or unable to comply with the treatment protocol including research tests.
  • Donor Inclusion Criteria:
• Related or Unrelated Donors:
  • °8/8 HLA matched at A, B, C, and DRB1 loci, as tested by DNA analysis.
• Able to provide informed consent for the donation process per institutional standards.
• Meet standard criteria for donor collection (e.g. National Marrow Donor Program Guidelines or collecting center guidelines as approved by treating physician).
• Provide GSCF mobilized peripheral blood stem cells

• Patients receiving first peripheral blood mobilized ex-vivo CD34-selected T cell depleted allo-HCT for the following hematologic malignant conditions:
  • Acute myeloid leukemia (AML) with intermediate or high-risk features in CR1 or Relapse AML in ≥ CR2.
  • Must have MRD <5% (flow cytometry, molecular and/or cytogenetics accepted).
  • Acute leukemias of ambiguous lineage in ≥ CR1.
  • Must have MRD <5% (flow cytometry, molecular and/or cytogenetics accepted).
  • Acute lymphoid leukemia (ALL) in CR1 with clinical, flow cytometric, or molecular features indicating a high risk for relapse, or ALL in ≥ CR2.
  • Adult Patients - recommended but not required to be MRDnegative (by flow cytometry, molecular and/or cytogenetics).
  • Pediatric Patients - Must be MRD-negative by flow cytometry, molecular and/or cytogenetics.
  • Myelodysplastic syndromes (MDS) with least one of the following:
  • Revised International Prognostic Scoring System risk score of intermediate or higher at the time of transplant evaluation.
  • Life-threatening cytopenia.
  • Karyotype or genomic changes that indicate high risk for progression to acute myelogenous leukemia, including abnormalities of chromosome 7 or 3, mutations of TP53, or complex or monosomal karyotype.
  • Therapy related disease or disease evolving from other malignant processes.
• Able to tolerate cytoreduction
• Patients age:
  • Regimen A: 4 - 60 years
  • Regimen B - no age restriction
• Adequate organ function is required, defined as follows:
  • Hepatic: Serum bilirubin ≤ 2 mg/dL, unless benign congenital hyperbilirubinemia. Patients with hyperbilirubinemia related to paroxysmal nocturnal hemoglobinuria or other hemolytic disorders are eligible with PI approval.
  • Hepatic: AST, ALT, and alkaline phosphatase < 2.5 times the upper limit of normal unless thought to be disease-related.
  • Renal: serum creatinine <1.5x normal for age. If serum creatinine is outside the normal range, then CrCl > 50 mL/min/1.73m2 (calculated or estimated) or GFR (mL/min/1.72m2) >30% of predicted normal for age.
• Normal GFR by Age
  • 1 week 40.6 + / - 14.8
  • 2 - 8 weeks 65.8 + / - 24.8
  • °> 8 weeks 95.7 +/- 21.7
  • 2 - 12 years 133 +/- 27
  • 13 - 21 years (males) 140 +/- 30
  • 13 - 21 years (females) 126.0 + / - 22.0
• Cardiac: LVEF ≥ 50% by MUGA or resting echocardiogram.
• Pulmonary: Pulmonary function testing (FEV1 and corrected DLCO) ≥ 50% predicted (pediatric patients unable to complete PFTs will need oxygen saturation as recorded by pulse oximetry of ≥92% on room air).
• Adequate performance status:
  • Age ≥ 16 years: ECOG ≤ 1 or Karnofsky 70%
  • Age < 16 years: Lansky 70%
• Each patient must be willing to participate as a research subject and must sign an informed consent form or legal guardian with assent as appropriate.